here are a plethora of epidemiological studies linking uric acid with incident hypertension [1] [2] [3] [4] and with cardiovascular events. 5 Some studies have shown a sex difference in cardiovascular events with the adverse cardiovascular association of uric acid seen only in women. [6] [7] [8] There is convincing evidence from animal studies that elevated uric acid has a detrimental effect on blood pressure (BP) and renal function. Administration of uric acid causes a rise in arterial BP in rat models 9 and sustained elevation of uric acid results in salt-sensitive hypertension and irreversible renal damage characterized by both arteriolar and glomerular damage. 10 Furthermore, the xanthine oxidase inhibitor allopurinol lowers BP in adolescents with hypertension and hyperuricemia 11 and both allopurinol and the uricosuric drug probenecid lower BP in obese adolescents with prehypertension. 12 A recent meta-analysis found that allopurinol lowers BP by 3/2 mm Hg in adults, 13 although this has never been tested in a specifically designed prospective study. Despite these results, there is still debate about a causal role for uric acid and the potential cardiovascular benefits of allopurinol may reflect either uric acid reduction or other mechanisms, such as superoxide anion reduction. 14 The association of uric acid with BP and kidney function suggests that uric acid levels may have implications in the clinical management of hypertension. The aim of this study is to determine whether baseline uric acid level, in patients attending a hypertension clinic, is associated with longitudinal BP level, renal function, and long-term cause-specific mortality in a sex-specific manner.
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A detailed description of the GBPC is given elsewhere. 15 Briefly, the GBPC provides secondary and tertiary level service to patients with hypertension in the West of Scotland. Data from patients attending the clinic are stored in a single computerized database, which contains information on individuals attending the clinic from the mid1970s to 2011. All patients are treated at the GBPC until they achieve target BP and are maintained at that level for ≤3 months. Currently, the database has information on >15 000 patients with hypertension. This study included patients who had their serum uric acid level measured at their first (registration) clinic visit. The West of Scotland research ethics service of the National Health Service has approved the study of the GBPC database (11/WS/0083). The study had no external funding.
Clinical Measurements
BP measurements were taken manually 3×, using standardized sphygmomanometers by specialist hypertension nurses; the mean of the last 2 measurements is recorded in the database at each visit. Patients attending the clinic were advised to take their regular medications as usual. Height and weight of all patients were measured using standardized equipment during each visit to calculate body mass index (BMI). Blood samples were collected at baseline and at regular intervals for estimation of routine hematologic and biochemical indices. All biochemical investigations were performed at the Western Infirmary clinical laboratory service. Uric acid level at first clinic visit was available in 6984 patients, and 1832 patients had ≤3 repeat uric acid measurements ≤1 year apart. Serum creatinine was measured routinely at baseline and during the follow-up period. Estimated glomerular filtration rate (eGFR) was estimated using Modification of Diet in Renal Disease equation. 16 A structured format was used to measure tobacco (any versus none) and alcohol use (quantity and frequency of consumption).
Outcome Assessment
Records kept by the General Register Office for Scotland ensured notification of a subject's death (provided that it occurred in the United Kingdom) together with the primary cause of death according to the International Classification of Diseases, 10th Revision (ICD-10), Version for 2007, codes. We considered cardiovascular deaths (cardiovascular mortality; ICD-10 codes I00-I99), ischemic heart disease deaths (mortality; ICD-10 codes I20-I25), and stroke deaths (stroke mortality; ICD-10 codes I60-I69) in the analysis. Deaths not caused by these conditions are classified as noncardiovascular deaths. Mortality data were collected up to April 2011.
Statistical Analysis
We divided our study population into sex-specific quartiles of serum uric acid levels because of between-sex differences in uric acid level. Differences in characteristics across the quartiles of serum uric acid level were explored using ANOVA (for continuous variables) and χ 2 test (for categorical variables).
First, we explored the relationship between quartiles of serum uric acid and longitudinal BP using generalized estimating equations (GEE). GEE is an extension of generalized linear model and often used in biomedical research when there is unknown correlation between repeat measurement data in longitudinal studies. 17 Individuals with ≤4 annual BP assessments in the first 5 years of follow-up and a 5-year minimum follow-up period were included in this analysis. Separate GEE models were used to study the relationship between serum uric acid in quartiles and follow-up systolic blood pressure (SBP) and diastolic blood pressure (DBP). The association was adjusted for baseline age, epochs, BMI, prevalent cardiovascular disease (CVD), alcohol and tobacco use, and eGFR level.
A second GEE model was generated for eGFR with the same covariates as above but excluding eGFR and including both SBP and DBP levels. Individuals with ≤4 annual eGFR assessments in the first 5 years of follow-up and survival up to a minimum of 5-year period were included. The analysis was also repeated in individuals with normal kidney function (eGFR>60 mL/min per 1.73 m 2 ) at baseline.
All nonmissing pairs of data were used in estimating the working correlation parameters. We then developed Kaplan-Meier time to event curves for sexspecific quartiles of serum uric acid. Cox proportional hazard models were used to analyze the relationship between baseline serum uric acid on all-cause, cardiovascular, ischemic heart disease, stroke, and noncardiovascular mortality. The covariates included were baseline age, sex, BMI, smoking status (never versus ever), SBP, DBP, alcohol use, baseline prevalence of CVD, and eGFR. A variable on year of first visit strata (epochs) was used to adjust the secular trend in mortality and was divided into 5 categories (first visit 1977  or before, between years 1978-1985, 1986-1993, 1994-2001, 2002 , and thereafter). The proportional hazards assumption was verified through examination of log-minus-log plots. Finally, a stratified Cox proportional hazard model (stratified based on concomitant use of diuretics at baseline) was developed. A regression spline Cox proportional hazard model was also set up to further smoothen the hazard functions, where serum uric acid was considered as a continuous variable along with all other covariates as described above. The relative hazard functions with associated 95% confidence intervals (CIs) were plotted in a graph using the mvrs algorithm in Stata. We performed additional sensitivity analyses, where lipid levels and blood glucose were added to the models and patients taking allopurinol were excluded. The discriminatory power of serum uric acid in predicting cardiovascular mortality was assessed using C statistics, 18 net-reclassification improvement, and integrated discrimination improvement. 19 Both net-reclassification improvement and integrated discrimination improvement measures of incremental value examine the extent to which a new marker reclassifies subjects. Stata Version 12.0 (Statacorp) was used for all statistical analysis.
Results

Demographic and Clinical Characteristics of the Study Population
A total of 6984 patients met the study inclusion criteria. Baseline characteristics are shown in Table 1 . The characteristics of included and excluded participants are shown in Table  S1 in the online-only Data Supplement. Of note, the mean age of included patients was 50.3 years (SD, 13.7), 52.6% were women, mean BMI was 27.4±5.3 kg/m 2 , mean baseline Continuous variables are expressed as mean (SD) and binary variables as n (%). BMI indicates body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, glomerular filtration rate; and SBP, systolic blood pressure. The characteristics of the study population stratified by quartiles of serum uric acid in men and women are given in Tables 2 and 3 . In men, baseline SBP, DBP, BMI, alcohol intake, use of diuretics, CKD, and attained DBP were higher in patients in the highest quartiles of serum uric acid. In women, age, SBP, DBP, BMI, hematocrit, attained SBP and DBP, alcohol intake, CKD, diuretic use, and preexisting CVD were higher in patients in the highest quartiles of serum uric acid.
Association of Serum Uric Acid With Longitudinal BP and eGFR
In the GEE analyses, serum uric acid at baseline did not predict the longitudinal changes in both SBP and DBP (Table 4) . However, there was a linear decrease in eGFR with increasing quartiles of serum uric acid in both men and women. Patients in the highest quartile of uric acid showed a 10.7 (95% CI, 13.6-7.9) mL/min per 1.73 m 2 and 12.2 (95% CI, 15.2-9.2) mL/min per 1.73 m 2 decrease in eGFR in men and women, respectively, compared with the lowest quartile. Consistent results were observed in the GEE analyses restricted to individuals with normal kidney function (eGFR >60) at baseline.
Survival Characteristics
The total time at risk in men and women was 56 529 and 67 704 patient years, respectively. The median survival time was 29 years Continuous variables are expressed as mean (SD) and binary variables as n (%). BMI indicates body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, filtration rate; and SBP, systolic blood pressure. Continuous variables are expressed as mean (SD) and binary variables as n (%). BMI indicates body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, filtration rate; and SBP, systolic blood pressure.
by guest on April 28, 2017 http://hyper.ahajournals.org/ Downloaded from in men, whereas it was 34 years in women. The incidence rates in men were 21.9 (95% CI, 20.7-23.1), 13.3 (95% CI, 12.4-14.3), and 8.6 (95% CI, 7.8-9.4) per 1000 patient years of follow-up for all-cause, CVD, and non-CVD mortality, respectively. In women, the incidence rates were 16.9 (95% CI, 15.9-17.9), 9.2 (95% CI, 8.5-9.9), and 7.7 (95% CI, 7.1-8.4) per 1000 patient years follow-up for all-cause, CVD, and non-CVD mortality, respectively.
Association Between Serum Uric Acid and Mortality
All-cause mortality did not differ across quartiles of serum uric acid in men (P=0.15) but was higher across quartiles in women (P<0.001; Figure 1) . Similarly, in the adjusted Cox proportional hazard models, serum uric acid quartiles did not influence mortality in men but did so in women (Table 5 ). In women, the hazard ratios for all-cause mortality were 1.26 (95% CI, 1.05-1.51) for the third and 1.38 (95% CI, 1.14-1.67) for the fourth quartiles compared with the first, respectively (Table 5) . Similar results were observed for both cardiovascular and ischemic heart disease mortality ( Table 5 ). The results of the regression spline analyses were similar (Figure 2 ) and results were not sensitive to addition of measures of blood glucose or lipid levels or exclusion of participants taking allopurinol (Table S2) . A positive linear association between serum uric acid and all-cause mortality was seen in the regression spline analyses in women without any threshold point.
Discriminatory Power of Serum Uric Acid in Predicting Cardiovascular Mortality
Reclassification analyses showed that the inclusion of uric acid improved cardiovascular mortality risk discrimination by 2% in women over and above conventional cardiovascular risk factors using C statistics but not in men ( Table 6 ). The net-reclassification improvement in the intermediate risk group (defined as 10-year cardiovascular risk of 10%-20%) in women was 3.8% (P=0.049).
Discussion
Our study aimed to explore the clinical significance of serum uric acid level in a large cohort of patients with treated hypertension from a large urban environment. We found no relationship between longitudinal change in BP and serum uric acid level in men or women but did find a significant relationship between uric acid level and change in renal function in both sexes. We found no association between serum uric acid and mortality from any or cardiovascular causes in men but found women in the highest 2 quartiles of serum uric acid level to have significantly increased all-cause and cardiovascular mortality. Recent clinical trials suggest that uric acid has a role in the development of hypertension, at least in adolescents and adolescents with obesity. 11, 12 This is supported by epidemiological data, 20 including studies in adult populations. [1] [2] [3] Our study included only adults with a known diagnosis of hypertension attending a specialist hypertension service. Little is known about the importance of uric acid level with regard to BP control in such patients. A previous analysis from the Framingham Heart Study found increased odds of progression of BP level but patients with hypertension were excluded from the analysis. 4 Our study found no evidence that increasing serum uric acid level has a detrimental effect on BP control in adults with treated hypertension, suggesting that uric acid level does not influence response to pharmacotherapy for hypertension.
We did find a significant relationship between uric acid level and deterioration in renal function in adults with treated hypertension. Those in the highest quartile of uric acid had a >10 mL/min per 1.73 m 2 deterioration in their eGFR compared with those in the lowest quartile, despite adjustment for age, sex, and BP level. Furthermore, results were similar when analysis was restricted to those with eGFR in the normal range. These results are in keeping with studies of rats, where hyperuricemia has been shown to induce renal arteriopathy and renal damage, 10, 21 although our data cannot establish causality or confirm that this has occurred in our patients. However, our findings are in keeping with previous studies showing a relationship between serum uric acid level and progression of renal disease in patients with type 1 diabetes mellitus, 22 in normotensive blood donors, 23 and a recent study showing an improvement in renal function after administration of rasburicase in elderly patients with hyperuricemia. 24 Small interventional trials have also shown improvement in renal function after allopurinol treatment in patients with both normal renal function 25 and CKD. 26 This supports our findings and suggests uric acid reduction may prevent decline in renal function, however larger studies with longer follow-up are required.
An association between elevated serum uric acid concentration and increased cardiovascular event rate, mortality, and all-cause mortality has been seen in several studies. 5, [27] [28] [29] We only saw this association in women, despite the fact that worsening eGFR was associated with higher serum uric acid in both sexes. In addition, we show that the additive prognostic value of uric acid in women is over and above the established cardiovascular risk factors as reflected in the net-reclassification improvement and integrated discrimination improvement. This indicates that there is clinical use in including uric acid in prognostic models only in women. Previous studies have also found this association to exist only in women (or to at least be more prominent). [6] [7] [8] There are known differences in uric acid metabolism between the sexes; women have a lower total body uric acid pool, presumably because of estrogen-mediated differences in renal excretion. 30 Unfortunately, we lack information on menopausal status but despite uric acid being higher in postmenopausal women, menopausal status has little effect on the association between uric acid and CVD. 31 It is, therefore, possible, but speculative, that raised serum uric acid in women reflects a different mechanism than in men, perhaps increased xanthine oxidase activity and the associated superoxide anion production. It is also possible that changes in uric acid have less impact on those with higher baseline risk and higher rates of traditional risk factors, such as the men studied here. However, our data raise the possibility that women with hyperuricemia may benefit from strategies to lower serum uric acid.
Our study has limitations, which include its observational nature and the study subjects derived from an urban hypertension clinic. All patients were on treatment for hypertension and attended a specialist hypertension service so our findings may not apply to untreated adults with hypertension or adults who are less intensively treated. This and the mean age of our sample (50 years) indicate that we cannot conclude whether serum uric acid level relates to BP control in younger adults, as it has been found in adolescents. Uric acid was not measured in all patients attending the clinic. It was a routine measurement after 1985, but was measured more intermittently before this date. There were some differences between those who did and did not have uric acid levels measured. There were no differences in age and CKD status, but patients with uric acid measurements had a slightly higher BP, although BP was elevated in both groups.
The strengths of our study include the large sample size with a long median survival time of 29 years in men and 34 years in women and an event rate sufficient to allow in depth analyses. Crucially, we have longitudinal measures of both BP control and renal function and so could explore the impact of serum uric level on long-term clinical outcomes. Follow-up measurements of uric acid in a subset of subjects indicate that the baseline uric acid levels were stable over the first 5 years of follow-up.
Perspectives
Serum uric acid has a role in the development of hypertension in adolescents, and strategies to lower serum uric acid also lower BP in this group. Animal models suggest that a sustained elevated serum uric acid level causes renal damage and salt-sensitive hypertension. We found that serum uric acid level was independently associated with decline in renal function in adults with treated hypertension attending a specialist service. This is in keeping with preclinical observations. However, we did not find a relationship between longitudinal BP control and uric acid level, suggesting that hyperuricemia does not alter the efficacy of contemporary hypertension management. We found that increased serum uric acid level is independently associated with cardiovascular and total mortality in women with hypertension, suggesting the ability of strategies to lower serum uric acid to reduce cardiovascular risk in this group should be explored. • Serum uric acid level does not predict long-term blood pressure control in a large population with treated hypertension.
• Higher baseline serum uric acid level is associated with subsequent decline in renal function.
• Higher serum uric acid level is associated with increased all-cause and cardiovascular mortality in women.
What Is Relevant?
• Our findings are in keeping with animal studies suggesting that sustained elevation in serum uric acid causes renal damage.
• Uric acid level may help identify women at excess cardiovascular risk and help identify patients with treated hypertension most at risk of decline in renal function.
Summary
Uric acid level should be measured in patients with hypertension and future studies should explore whether uric acid reduction improves renal function in patients with hyperuricemia and reduces cardiovascular event rate in women with hyperuricemia. 
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